# LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

> **NCT07100067** · NA · RECRUITING · sponsor: **Nanjing Legend Biotech Co.** · enrollment: 35 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma(MM)

## Interventions

- **BIOLOGICAL:** LCAR- F33S cells intravenous infusion

## Key facts

- **NCT ID:** NCT07100067
- **Lead sponsor:** Nanjing Legend Biotech Co.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-16
- **Primary completion:** 2028-02-20
- **Final completion:** 2029-11-20
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07100067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07100067, "LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07100067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*